Selected research
Industry Research
Humanized Monoclonal Antibody Drugs Industry Research Report 2026
Market perspective
The global Humanized Monoclonal Antibody Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Humanized Monoclonal Antibody Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Humanized Monoclonal Antibody Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Humanized Monoclonal Antibody Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Humanized Monoclonal Antibody Drugs include Innovent Bio, Takeda, Teva, Sun Pharmaceutical, Johnson & Johnson, Qilu Pharma, Novartis, Merck & Co and Roche, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Humanized Monoclonal Antibody Drugs market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Humanized Monoclonal Antibody Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Humanized Monoclonal Antibody Drugs Market by Company
Innovent Bio
Takeda
Teva
Sun Pharmaceutical
Johnson & Johnson
Qilu Pharma
Novartis
Merck & Co
Roche
Eli Lilly & Co
Pfizer
Beigene
GlaxoSmithKline
Biogen
AbbVie
AstraZeneca
UCB
Gilead Sciences
Humanized Monoclonal Antibody Drugs Segment by Type
Ixekizumab
Vedolizumab
Risenqizumab
Trastuzumab
Pembrolizumab
Farisimab
Bevacizumab
Orelizumab
Omalizumab
Other
Humanized Monoclonal Antibody Drugs Segment by Application
Cancers
Inflammatory Condition
Autoimmune Diseases
Humanized Monoclonal Antibody Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Humanized Monoclonal Antibody Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Humanized Monoclonal Antibody Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Humanized Monoclonal Antibody Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Humanized Monoclonal Antibody Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ixekizumab
- Vedolizumab
- Risenqizumab
- Trastuzumab
- Pembrolizumab
- Farisimab
- Bevacizumab
- Orelizumab
- Omalizumab
- Other
Applications
- Cancers
- Inflammatory Condition
- Autoimmune Diseases
Companies covered
- Innovent Bio
- Takeda
- Teva
- Sun Pharmaceutical
- Johnson & Johnson
- Qilu Pharma
- Novartis
- Merck & Co
- Roche
- Eli Lilly & Co
- Pfizer
- Beigene
- GlaxoSmithKline
- Biogen
- AbbVie
- AstraZeneca
- UCB
- Gilead Sciences
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Humanized Monoclonal Antibody Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Ixekizumab
- 2.2.3 Vedolizumab
- 2.2.4 Risenqizumab
- 2.2.5 Trastuzumab
- 2.2.6 Pembrolizumab
- 2.2.7 Farisimab
- 2.2.8 Bevacizumab
- 2.2.9 Orelizumab
- 2.2.10 Omalizumab
- 2.2.11 Other
- 2.3 Humanized Monoclonal Antibody Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cancers
- 2.3.3 Inflammatory Condition
- 2.3.4 Autoimmune Diseases
- 2.4 Assumptions and Limitations
3 Humanized Monoclonal Antibody Drugs Breakdown Data by Type
- 3.1 Global Humanized Monoclonal Antibody Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Humanized Monoclonal Antibody Drugs Forecasted Market Size by Type (2027-2032)
4 Humanized Monoclonal Antibody Drugs Breakdown Data by Application
- 4.1 Global Humanized Monoclonal Antibody Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Humanized Monoclonal Antibody Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Humanized Monoclonal Antibody Drugs Market Perspective (2021-2032)
- 5.2 Global Humanized Monoclonal Antibody Drugs Growth Trends by Region
- 5.2.1 Global Humanized Monoclonal Antibody Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Humanized Monoclonal Antibody Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Humanized Monoclonal Antibody Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Humanized Monoclonal Antibody Drugs Market Dynamics
- 5.3.1 Humanized Monoclonal Antibody Drugs Industry Trends
- 5.3.2 Humanized Monoclonal Antibody Drugs Market Drivers
- 5.3.3 Humanized Monoclonal Antibody Drugs Market Challenges
- 5.3.4 Humanized Monoclonal Antibody Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Humanized Monoclonal Antibody Drugs Players by Revenue
- 6.1.1 Global Top Humanized Monoclonal Antibody Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Humanized Monoclonal Antibody Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Humanized Monoclonal Antibody Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Humanized Monoclonal Antibody Drugs Head Office and Area Served
- 6.4 Global Humanized Monoclonal Antibody Drugs Players, Product Type & Application
- 6.5 Global Humanized Monoclonal Antibody Drugs Manufacturers Established Date
- 6.6 Global Humanized Monoclonal Antibody Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Humanized Monoclonal Antibody Drugs Market Size (2021-2032)
- 7.2 North America Humanized Monoclonal Antibody Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026)
- 7.4 North America Humanized Monoclonal Antibody Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Humanized Monoclonal Antibody Drugs Market Size (2021-2032)
- 8.2 Europe Humanized Monoclonal Antibody Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026)
- 8.4 Europe Humanized Monoclonal Antibody Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Humanized Monoclonal Antibody Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Humanized Monoclonal Antibody Drugs Market Size (2021-2032)
- 10.2 South America Humanized Monoclonal Antibody Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026)
- 10.4 South America Humanized Monoclonal Antibody Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Humanized Monoclonal Antibody Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Innovent Bio
- 12.1.1 Innovent Bio Company Information
- 12.1.2 Innovent Bio Business Overview
- 12.1.3 Innovent Bio Revenue in Humanized Monoclonal Antibody Drugs Business (2021-2026)
- 12.1.4 Innovent Bio Humanized Monoclonal Antibody Drugs Product Portfolio
- 12.1.5 Innovent Bio Recent Developments
- 12.2 Takeda
- 12.2.1 Takeda Company Information
- 12.2.2 Takeda Business Overview
- 12.2.3 Takeda Revenue in Humanized Monoclonal Antibody Drugs Business (2021-2026)
- 12.2.4 Takeda Humanized Monoclonal Antibody Drugs Product Portfolio
- 12.2.5 Takeda Recent Developments
- 12.3 Teva
- 12.3.1 Teva Company Information
- 12.3.2 Teva Business Overview
- 12.3.3 Teva Revenue in Humanized Monoclonal Antibody Drugs Business (2021-2026)
- 12.3.4 Teva Humanized Monoclonal Antibody Drugs Product Portfolio
- 12.3.5 Teva Recent Developments
- 12.4 Sun Pharmaceutical
- 12.4.1 Sun Pharmaceutical Company Information
- 12.4.2 Sun Pharmaceutical Business Overview
- 12.4.3 Sun Pharmaceutical Revenue in Humanized Monoclonal Antibody Drugs Business (2021-2026)
- 12.4.4 Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Product Portfolio
- 12.4.5 Sun Pharmaceutical Recent Developments
- 12.5 Johnson & Johnson
- 12.5.1 Johnson & Johnson Company Information
- 12.5.2 Johnson & Johnson Business Overview
- 12.5.3 Johnson & Johnson Revenue in Humanized Monoclonal Antibody Drugs Business (2021-2026)
- 12.5.4 Johnson & Johnson Humanized Monoclonal Antibody Drugs Product Portfolio
- 12.5.5 Johnson & Johnson Recent Developments
- 12.6 Qilu Pharma
- 12.6.1 Qilu Pharma Company Information
- 12.6.2 Qilu Pharma Business Overview
- 12.6.3 Qilu Pharma Revenue in Humanized Monoclonal Antibody Drugs Business (2021-2026)
- 12.6.4 Qilu Pharma Humanized Monoclonal Antibody Drugs Product Portfolio
- 12.6.5 Qilu Pharma Recent Developments
- 12.7 Novartis
- 12.7.1 Novartis Company Information
- 12.7.2 Novartis Business Overview
- 12.7.3 Novartis Revenue in Humanized Monoclonal Antibody Drugs Business (2021-2026)
- 12.7.4 Novartis Humanized Monoclonal Antibody Drugs Product Portfolio
- 12.7.5 Novartis Recent Developments
- 12.8 Merck & Co
- 12.8.1 Merck & Co Company Information
- 12.8.2 Merck & Co Business Overview
- 12.8.3 Merck & Co Revenue in Humanized Monoclonal Antibody Drugs Business (2021-2026)
- 12.8.4 Merck & Co Humanized Monoclonal Antibody Drugs Product Portfolio
- 12.8.5 Merck & Co Recent Developments
- 12.9 Roche
- 12.9.1 Roche Company Information
- 12.9.2 Roche Business Overview
- 12.9.3 Roche Revenue in Humanized Monoclonal Antibody Drugs Business (2021-2026)
- 12.9.4 Roche Humanized Monoclonal Antibody Drugs Product Portfolio
- 12.9.5 Roche Recent Developments
- 12.10 Eli Lilly & Co
- 12.10.1 Eli Lilly & Co Company Information
- 12.10.2 Eli Lilly & Co Business Overview
- 12.10.3 Eli Lilly & Co Revenue in Humanized Monoclonal Antibody Drugs Business (2021-2026)
- 12.10.4 Eli Lilly & Co Humanized Monoclonal Antibody Drugs Product Portfolio
- 12.10.5 Eli Lilly & Co Recent Developments
- 12.11 Pfizer
- 12.11.1 Pfizer Company Information
- 12.11.2 Pfizer Business Overview
- 12.11.3 Pfizer Revenue in Humanized Monoclonal Antibody Drugs Business (2021-2026)
- 12.11.4 Pfizer Humanized Monoclonal Antibody Drugs Product Portfolio
- 12.11.5 Pfizer Recent Developments
- 12.12 Beigene
- 12.12.1 Beigene Company Information
- 12.12.2 Beigene Business Overview
- 12.12.3 Beigene Revenue in Humanized Monoclonal Antibody Drugs Business (2021-2026)
- 12.12.4 Beigene Humanized Monoclonal Antibody Drugs Product Portfolio
- 12.12.5 Beigene Recent Developments
- 12.13 GlaxoSmithKline
- 12.13.1 GlaxoSmithKline Company Information
- 12.13.2 GlaxoSmithKline Business Overview
- 12.13.3 GlaxoSmithKline Revenue in Humanized Monoclonal Antibody Drugs Business (2021-2026)
- 12.13.4 GlaxoSmithKline Humanized Monoclonal Antibody Drugs Product Portfolio
- 12.13.5 GlaxoSmithKline Recent Developments
- 12.14 Biogen
- 12.14.1 Biogen Company Information
- 12.14.2 Biogen Business Overview
- 12.14.3 Biogen Revenue in Humanized Monoclonal Antibody Drugs Business (2021-2026)
- 12.14.4 Biogen Humanized Monoclonal Antibody Drugs Product Portfolio
- 12.14.5 Biogen Recent Developments
- 12.15 AbbVie
- 12.15.1 AbbVie Company Information
- 12.15.2 AbbVie Business Overview
- 12.15.3 AbbVie Revenue in Humanized Monoclonal Antibody Drugs Business (2021-2026)
- 12.15.4 AbbVie Humanized Monoclonal Antibody Drugs Product Portfolio
- 12.15.5 AbbVie Recent Developments
- 12.16 AstraZeneca
- 12.16.1 AstraZeneca Company Information
- 12.16.2 AstraZeneca Business Overview
- 12.16.3 AstraZeneca Revenue in Humanized Monoclonal Antibody Drugs Business (2021-2026)
- 12.16.4 AstraZeneca Humanized Monoclonal Antibody Drugs Product Portfolio
- 12.16.5 AstraZeneca Recent Developments
- 12.17 UCB
- 12.17.1 UCB Company Information
- 12.17.2 UCB Business Overview
- 12.17.3 UCB Revenue in Humanized Monoclonal Antibody Drugs Business (2021-2026)
- 12.17.4 UCB Humanized Monoclonal Antibody Drugs Product Portfolio
- 12.17.5 UCB Recent Developments
- 12.18 Gilead Sciences
- 12.18.1 Gilead Sciences Company Information
- 12.18.2 Gilead Sciences Business Overview
- 12.18.3 Gilead Sciences Revenue in Humanized Monoclonal Antibody Drugs Business (2021-2026)
- 12.18.4 Gilead Sciences Humanized Monoclonal Antibody Drugs Product Portfolio
- 12.18.5 Gilead Sciences Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst